{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:03:46Z","timestamp":1789718626614,"version":"4.0.1"},"reference-count":27,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2026,8,13]]},"abstract":"<jats:p xml:lang=\"en\">Aim: Treatment approaches for biliary tract cancer (BTC) vary widely. Genomic profiling through next-generation sequencing (NGS) has made it possible to apply precision medicine in the management of BTC. This retrospective observational study aimed to evaluate the implementation of treatments based on identified genomic mutations and their clinical significance in patients with BTC in Japan, where NGS is covered by health insurance. Methods: We conducted a retrospective analysis of 65 patients with unresectable or recurrent BTC who underwent comprehensive genomic profiling at a single institution between November 2019 and October 2024. Genomic mutations were classified according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scale. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Results: Among the 65 patients, clinically relevant genomic mutations classified using the ESCAT scale were identified in 47 patients, and clinically treatable genomic mutations were identified in 13 patients. Six patients ultimately received mutation-guided therapy, including fibroblast growth factor receptor inhibitors and pembrolizumab. The median time from specimen submission to review by the expert panel was 26 (range, 16\u201340) days. No significant difference in OS was observed based on the site of the primary tumor (log-rank test, P = 0.5804). Conclusions: Although clinically actionable genomic mutations were identified in one-fifth of patients, &lt; 10% ultimately received treatment based on those findings, highlighting a gap between genomic profiling and treatment implementation. In contrast, with the increasing number of available therapies, access to precision treatment for patients with BTC may improve in the future through a combination of early adoption of NGS and the complementary use of liquid biopsy when tissue is unavailable.<\/jats:p>","DOI":"10.37349\/etat.2026.1002402","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:31:24Z","timestamp":1789716684000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution"],"prefix":"10.37349","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3058-5674","authenticated-orcid":false,"given":"Kei","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan; Division of Hepato-Biliary and Pancreatic Surgery, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9688-4956","authenticated-orcid":false,"given":"Hideaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-3810","authenticated-orcid":false,"given":"Masahiro","family":"Iseki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4582-6589","authenticated-orcid":false,"given":"Daisuke","family":"Douchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-0236","authenticated-orcid":false,"given":"Shuichi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6416","authenticated-orcid":false,"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i10.110415","article-title":"Current insights and future perspectives of treatment strategies for biliary tract cancer","volume":"17","author":"Nakagawa","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/nejmoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401 - MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/jco-24-01383","article-title":"SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.cd-22-0417","article-title":"C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ng.3386","article-title":"Building a staircase to precision medicine for biliary tract cancer","volume":"47","author":"Razumilava","year":"2015","journal-title":"Nat Genet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/cts.13660","article-title":"Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study","volume":"16","author":"Maeda","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100092","article-title":"The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification","volume":"6","author":"Rahmani","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860453","article-title":"Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives","volume":"12","author":"Zugman","year":"2022","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00535-020-01735-2","article-title":"Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)","volume":"56","author":"Maruki","year":"2021","journal-title":"J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/liv.15984","article-title":"Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis","volume":"44","author":"Niu","year":"2024","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/s1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00535-025-02303-2","article-title":"Molecular insights into HER2\/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction","volume":"61","author":"Zhu","year":"2025","journal-title":"J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of Cancer Risk Profile for","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.ccr-21-2384","article-title":"ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091579","article-title":"Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples","volume":"17","author":"Arreaza","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:31:25Z","timestamp":1789716685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":27,"URL":"https:\/\/doi.org\/10.37349\/etat.2026.1002402","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2026-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002402"}}